Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Autor: David Hillus, Tatjana Schwarz, Pinkus Tober-Lau, Kanika Vanshylla, Hana Hastor, Charlotte Thibeault, Stefanie Jentzsch, Elisa T Helbig, Lena J Lippert, Patricia Tscheak, Marie Luisa Schmidt, Johanna Riege, André Solarek, Christof von Kalle, Chantip Dang-Heine, Henning Gruell, Piotr Kopankiewicz, Norbert Suttorp, Christian Drosten, Harald Bias, Joachim Seybold, Florian Klein, Florian Kurth, Victor Max Corman, Leif Erik Sander, Ben Al-Rim, Lara Bardtke, Jörn Ilmo Beheim-Schwarzbach, Kerstin Behn, Leon Bergfeld, Norma Bethke, Tobias Bleicker, Dana Briesemeister, Sophia Brumhard, Claudia Conrad, Sebastian Dieckmann, Doris Frey, Julie-Anne Gabelich, Philipp Georg, Ute Gläser, Lisbeth Hasler, Andreas Hetey, Anna Luisa Hiller, Alexandra Horn, Claudia Hülso, Luisa Kegel, Willi Koch, Alexander Krannich, Paolo Kroneberg, Michelle Lisy, Petra Mackeldanz, Birgit Maeß, Friederike Münn, Nadine Olk, Christian Peiser, Kai Pohl, Annelie Hermel, Maria Rönnefarth, Carolin Rubisch, Angela Sanchez Rezza, Isabelle Schellenberger, Viktoria Schenkel, Jenny Schlesinger, Sein Schmidt, Georg Schwanitz, Anne-Sophie Sinnigen, Paula Stubbemann, Julia Tesch, Denise Treue, Daniel Wendisch, Saskia Zvorc

Publikováno v: The Lancet. Respiratory Medicine

Background Heterologous vaccine regimens have been widely discussed as a way to mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 vaccines. We aimed to assess the reactogenicity and immunogenicity of heterolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c3eba2e3cfb401ade71e099f81b538
https://doi.org/10.1016/s2213-2600(21)00357-x